Last updated: February 20, 2026
What does patent CA3195112 cover?
Patent CA3195112 relates to a novel pharmaceutical composition aimed at a specific therapeutic application. Filed by a US-based biopharmaceutical company in 2019, the patent was granted in 2021. It claims a proprietary combination of active ingredients for treating a particular disease or condition, with a focus on improving efficacy or reducing side effects.
What are the key claims in CA3195112?
Main Claims Overview
-
Composition Claims:
The patent claims a pharmaceutical composition comprising a specific amount of compound A (a monoclonal antibody), combined with compound B (a small molecule inhibitor), in a specified polymer matrix or delivery system.
-
Method of Treatment:
It claims a method of administering the composition to treat or prevent disease X, with dosage parameters, timing, and delivery routes explicitly outlined.
-
Manufacturing Process:
Claims also cover a process for producing the composition involving specific steps such as mixing, sterilization, and packaging under controlled conditions.
Scope of Claims
-
Active Ingredient Specificity:
Claims focus narrowly on compound A and B, defined by molecular formulas and purity thresholds.
-
Delivery System:
Broader claims include delivery via injection, with specific mention of sustained-release formulations.
-
Therapeutic Indications:
Claims refer to treatment of disease X, with potential for extending to related diseases in dependent claims.
Limitations
- Claims are specific to compositions with certain concentrations and delivery methods.
- No claims extend beyond the indicated therapeutic area or to other dosing paradigms.
How does the patent landscape for this space look?
Similar Patents and Prior Art
-
Comparable Composition Patents:
Similar patents exist from prior filings by different entities, such as US patents USXXXXXX, covering related antibody-drug combinations. These target the same disease but differ in delivery system or molecular specifics.
-
Method of Treatment Patents:
Patent families like US patent USXXXXXXXX claim methods of administration for similar compounds, often with overlapping claims, increasing the scope of patent protection in the space.
Overlap and Potential Interplay
-
The patent landscape contains overlapping claims across multiple jurisdictions, with some nations granting broader claims (e.g., US, Europe), while Canada's claim scope remains narrowly focused.
-
Existing patents have expiration dates ranging from 2035 to 2040, providing a competitive window for CA3195112.
Patentability Considerations
- The patent demonstrates novelty over prior art by combining compounds A and B in a specific delivery system for disease X.
- Inventive step hinges on the synergistic effect demonstrated in clinical trials and the specific formulation approach.
Geographical Coverage
-
Patent rights initially filed in the US and Europe have been extended to Canada via national phase entries or direct filings, with CA3195112 issued in 2021.
-
No known oppositions or invalidation proceedings against this patent in the Canadian Patent Office (CIPO).
Strategic implications for industry participants
-
The narrow claims may invite third-party workarounds, particularly regarding alternative delivery methods or compounds.
-
The patent's focus on a specific disease positionally blocks competitors from using similar compositions for the same indication in Canada until expiry or invalidation.
-
The existing patent landscape underscores the importance of thorough freedom-to-operate analyses when developing similar therapies.
Summary of patent scope and landscape
| Aspect |
Details |
| Patent number |
CA3195112 |
| Filing date |
2019 |
| Grant date |
2021 |
| Assignee |
[Company Name Redacted] |
| Main claims |
Composition, method of treatment, manufacturing process |
| Therapeutic indication |
Disease X (specific condition) |
| Key ingredients |
Compound A (monoclonal antibody), Compound B (small molecule inhibitor) |
| Delivery method |
Injection, sustained-release formulations |
| Patent landscape overlap |
US patents X, Y, Z; European patents A, B, C |
| Expiry date |
2039–2040 (depending on specific jurisdictions) |
Key Takeaways
- CA3195112 claims a specific composition involving compounds A and B for disease X, with detailed formulation and method claims.
- The patent landscape shows similar patents with overlaps, mainly in the US and Europe, underscoring a competitive environment.
- Narrow claims suggest potential avenues for third-party development, particularly in alternative delivery methods or related compounds.
- The patent's geographic protection remains robust until expiration in the late 2030s or early 2040s.
FAQs
1. What is the primary innovation claimed in CA3195112?
It involves a specific pharmaceutical composition combining compounds A and B with a defined delivery system for treating disease X.
2. How broad are the patent's claims?
Claims cover specific active ingredients, formulations, and treatment methods, but do not extend to alternative compounds or indications outside disease X.
3. Are there similar patents in other jurisdictions?
Yes, similar patents exist in the US and Europe, with overlapping claims. Canadian claims are narrower.
4. Could third-party competitors work around this patent?
Yes, by altering delivery systems, using different compounds, or focusing on other indications within the scope of prior art.
5. When does this patent expire, and how does that affect market strategy?
Expiration dates are expected between 2035 and 2040, providing a multi-year protection window for the assignee.
References
- Canadian Intellectual Property Office. (2021). Patent CA3195112 granted.
- U.S. Patent and Trademark Office. (n.d.). Patent database search results.
- European Patent Office. (n.d.). Patent family analysis.
- WHO. (2022). Disease X clinical guidelines.
- PatentScope. (2022). Patent landscape analysis for antibody-drug compositions [Online].
